Literature DB >> 31844006

The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris.

Nathan P Wiederhold1, Laura K Najvar2,3, Rosie Jaramillo2,3, Marcos Olivo2,3, Hoja Patterson2, April Connell2, Yoshiko Fukuda4, Junichi Mitsuyama4, Gabriel Catano2,3, Thomas F Patterson2,3.   

Abstract

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log10 CFU/g) compared to control (0% survival and 7.09 log10 CFU/g) (P < 0.01).
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Candida auris; T-2307; caspofungin; fluconazole; in vitro susceptibility; invasive candidiasis; murine model

Mesh：

Substances：

Year:  2020        PMID： 31844006      PMCID： PMC7038306          DOI： 10.1128/AAC.02198-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris.

Authors:  Nathan P Wiederhold; Shawn R Lockhart; Laura K Najvar; Elizabeth L Berkow; Rosie Jaramillo; Marcos Olivo; Edward P Garvey; Christopher M Yates; Robert J Schotzinger; Gabriel Catano; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

2.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.

Authors:  Shawn R Lockhart; Kizee A Etienne; Snigdha Vallabhaneni; Joveria Farooqi; Anuradha Chowdhary; Nelesh P Govender; Arnaldo Lopes Colombo; Belinda Calvo; Christina A Cuomo; Christopher A Desjardins; Elizabeth L Berkow; Mariana Castanheira; Rindidzani E Magobo; Kauser Jabeen; Rana J Asghar; Jacques F Meis; Brendan Jackson; Tom Chiller; Anastasia P Litvintseva
Journal:  Clin Infect Dis       Date:  2016-10-20       Impact factor: 9.079

3.  Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice.

Authors:  Masahiro Abe; Shigeki Nakamura; Yuki Kinjo; Yuka Masuyama; Junichi Mitsuyama; Mitsuo Kaku; Yoshitsugu Miyazaki
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

4.  Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016.

Authors:  Snigdha Vallabhaneni; Alex Kallen; Sharon Tsay; Nancy Chow; Rory Welsh; Janna Kerins; Sarah K Kemble; Massimo Pacilli; Stephanie R Black; Emily Landon; Jessica Ridgway; Tara N Palmore; Adrian Zelzany; Eleanor H Adams; Monica Quinn; Sudha Chaturvedi; Jane Greenko; Rafael Fernandez; Karen Southwick; E Yoko Furuya; David P Calfee; Camille Hamula; Gopi Patel; Patricia Barrett; Patricia Lafaro; Elizabeth L Berkow; Heather Moulton-Meissner; Judith Noble-Wang; Ryan P Fagan; Brendan R Jackson; Shawn R Lockhart; Anastasia P Litvintseva; Tom M Chiller
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-11       Impact factor: 17.586

5.  Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Lei Ma; Mark R Deziel; Michael F Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

6.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.

Authors:  Hiroshi Nishikawa; Yoshiko Fukuda; Junichi Mitsuyama; Masato Tashiro; Akitaka Tanaka; Takahiro Takazono; Tomomi Saijo; Kazuko Yamamoto; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Hiroshi Mukae; Shigeru Kohno; Koichi Izumikawa
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

7.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.

Authors:  Junichi Mitsuyama; Nobuhiko Nomura; Kyoko Hashimoto; Eio Yamada; Hiroshi Nishikawa; Makoto Kaeriyama; Akiko Kimura; Yozo Todo; Hirokazu Narita
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

8.  T-2307 causes collapse of mitochondrial membrane potential in yeast.

Authors:  Tatsuya Shibata; Toshinari Takahashi; Eio Yamada; Akiko Kimura; Hiroshi Nishikawa; Hiroyoshi Hayakawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

Review 9.  Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally.

Authors:  Anuradha Chowdhary; Cheshta Sharma; Jacques F Meis
Journal:  PLoS Pathog       Date:  2017-05-18       Impact factor: 6.823

10.  Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Karen J Shaw; Rosie Jaramillo; Hoja Patterson; Marcos Olivo; Gabriel Catano; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191
View more
  9 in total

Review 1.  Emerging and future strategies in the management of recalcitrant Candida auris.

Authors:  Nihal Bandara; Lakshman Samaranayake
Journal:  Med Mycol       Date:  2022-03-17       Impact factor: 4.076

Review 2.  Candida auris, a singular emergent pathogenic yeast: its resistance and new therapeutic alternatives.

Authors:  Liliana Fernandes; Rita Ribeiro; Mariana Henriques; Maria Elisa Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-10-06       Impact factor: 5.103

3.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

4.  Current and promising pharmacotherapeutic options for candidiasis.

Authors:  Liliana Scorzoni; Beth Burgwyn Fuchs; Juliana Campos Junqueira; Eleftherios Mylonakis
Journal:  Expert Opin Pharmacother       Date:  2021-02-04       Impact factor: 3.889

Review 5.  Candida auris: A Quick Review on Identification, Current Treatments, and Challenges.

Authors:  Lucia Černáková; Maryam Roudbary; Susana Brás; Silva Tafaj; Célia F Rodrigues
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

Review 6.  Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.

Authors:  Sarah E Murphy; Tihana Bicanic
Journal:  Front Cell Infect Microbiol       Date:  2021-12-14       Impact factor: 6.073

Review 7.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 8.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

Review 9.  Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris.

Authors:  Muriel Billamboz; Zeeshan Fatima; Saif Hameed; Samir Jawhara
Journal:  Microorganisms       Date:  2021-03-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.